Literature DB >> 17942522

The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.

L Costelloe1, K O'Rourke, C McGuigan, C Walsh, N Tubridy, M Hutchinson.   

Abstract

BACKGROUND: To examine the longitudinal relationship between the patient-rated Multiple Sclerosis Impact Scale (MSIS-29) and the doctor-reported Multiple Sclerosis Functional Composite (MSFC).
METHODS: Two-hundred and four MS patients at baseline and 150 patients one to three years later had MSFC and MSIS-29 assessments. Cross-sectional correlations between these measures and correlations of change in scores were examined. Minimally important change (MIC) in the MSFC was defined at either 0.5 or 0.32 SD from baseline. Effect sizes (ES) were calculated. VALIDITY: The MSIS-29 physical correlated moderately with the total MSFC score and the 25-foot timed walk and 9-hole peg test. Correlations of the MSIS-29 physical with the PASAT, and the MSFC with the MSIS-29 psychological were weak. Responsiveness: When MIC in the MSFC was defined as 0.5, mean MSIS-29 physical change was 11.26 (ES = 0.53). At MSFC change of 0.32, mean MSIS-29 physical change was 10.4 (ES = 0.52). Change in MSFC scores correlated weakly with change in the MSIS-29 scores. Stability: In patients with stable MSFC scores, the mean MSIS-29 physical scores improved minimally over time with negligible ES.
CONCLUSIONS: Although the MSIS-29 physical demonstrates moderate cross-sectional correlation with the MSFC, the weak correlations of change scores between the two instruments indicate that they measure different aspects of the effects of multiple sclerosis morbidity.

Entities:  

Mesh:

Year:  2007        PMID: 17942522     DOI: 10.1177/1352458507081274

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  11 in total

1.  Psychometric properties of measures of upper limb activity performance in adults with and without spasticity undergoing neurorehabilitation-A systematic review.

Authors:  Shannon Pike; Anne Cusick; Kylie Wales; Lisa Cameron; Lynne Turner-Stokes; Stephen Ashford; Natasha A Lannin
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

2.  Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2011-08-24       Impact factor: 4.849

Review 3.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

4.  Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Authors:  Lars G Hvid; Egon Stenager; Ulrik Dalgas
Journal:  J Neurol       Date:  2022-04-28       Impact factor: 6.682

5.  Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.

Authors:  Claire M Rice; David I Marks; Yoav Ben-Shlomo; Nikos Evangelou; Paul S Morgan; Chris Metcalfe; Peter Walsh; Nick M Kane; Martin G Guttridge; Gail Miflin; Stuart Blackmore; Pamela Sarkar; Juliana Redondo; Denise Owen; David A Cottrell; Alastair Wilkins; Neil J Scolding
Journal:  Trials       Date:  2015-10-14       Impact factor: 2.279

6.  Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.

Authors:  E D Bacci; K W Wyrwich; G A Phillips; T Vollmer; S Guo
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-10-09

Review 7.  Outcome Measures in Clinical Trials for Multiple Sclerosis.

Authors:  Caspar E P van Munster; Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

8.  Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).

Authors:  Claire M Rice; David I Marks; Peter Walsh; Nick M Kane; Martin G Guttridge; Juliana Redondo; Pamela Sarkar; Denise Owen; Alastair Wilkins; Neil J Scolding
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

9.  Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.

Authors:  Glenn A Phillips; Kathleen W Wyrwich; Shien Guo; Rossella Medori; Arman Altincatal; Linda Wagner; Jacob Elkins
Journal:  Mult Scler       Date:  2014-04-16       Impact factor: 6.312

10.  Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Authors:  Stanley Cohan; Ludwig Kappos; Gavin Giovannoni; Heinz Wiendl; Krzysztof Selmaj; Eva Kubala Havrdová; John Rose; Steven Greenberg; Glenn Phillips; Wei Ma; Ping Wang; Gabriel Lima; Guido Sabatella
Journal:  Mult Scler       Date:  2017-10-06       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.